Andreas Maxeiner1,2, Christen B. Adkins2, W. Scott McDougal3, Chin Lee Wu3,4, Leo Ling Cheng4,5
1Radiology and Urology, Charit Universittsmedizin Berlin , Germany; 2Pathology , Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 3Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 4Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 5Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Recognizing the lack of effective clinical protocol for the evaluation of prostate cancer (PCa) recurrence potentials after prostatectomy, this study retrospectively evaluates the ability of tissue magnetic resonance spectroscopy (MRS) metabolomic profiles to identify PCa recurrence. Sixteen PCa-recurrent cases were paired with age- and Gleason-score-matched cases without recurrence and of the same pathological stage (n=16) or clinical stage (n=16). Metabolomic profiles from statistical analyses of the 27 most common and intensive spectral and metabolic regions from clinical-stage-matched groups can identify recurrence (P < 0.008). Applying the profiles onto the pathological-stage-matched groups, the overall 73.9% accuracy in identifying recurrence was reached.